These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 21787240)
1. New β-glucan inhibitors as antifungal drugs. Hector RF; Bierer DE Expert Opin Ther Pat; 2011 Oct; 21(10):1597-610. PubMed ID: 21787240 [TBL] [Abstract][Full Text] [Related]
2. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Apgar JM; Wilkening RR; Parker DL; Meng D; Wildonger KJ; Sperbeck D; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Nielsen Kahn J; Powles M; Racine F; Dragovic J; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M Bioorg Med Chem Lett; 2021 Jan; 32():127661. PubMed ID: 33160023 [TBL] [Abstract][Full Text] [Related]
3. Ibrexafungerp: A novel oral glucan synthase inhibitor. Davis MR; Donnelley MA; Thompson GR Med Mycol; 2020 Jul; 58(5):579-592. PubMed ID: 31342066 [TBL] [Abstract][Full Text] [Related]
4. Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin. Apgar JM; Wilkening RR; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Nielsen Kahn J; Powles M; Racine F; Dragovic J; Habulihaz B; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M Bioorg Med Chem Lett; 2015 Dec; 25(24):5813-8. PubMed ID: 26542966 [TBL] [Abstract][Full Text] [Related]
5. Medical claims and current applications of the potent echinocandin antifungals. Smith L; Lu SE Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):58-63. PubMed ID: 19929842 [TBL] [Abstract][Full Text] [Related]
6. Novel antifungal agents: a patent review (2013 - present). Victoria Castelli M; Gabriel Derita M; Noelí López S Expert Opin Ther Pat; 2017 Apr; 27(4):415-426. PubMed ID: 27897041 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase. Heasley BH; Pacofsky GJ; Mamai A; Liu H; Nelson K; Coti G; Peel MR; Balkovec JM; Greenlee ML; Liberator P; Meng D; Parker DL; Wilkening RR; Apgar JM; Racine F; Hsu MJ; Giacobbe RA; Kahn JN Bioorg Med Chem Lett; 2012 Nov; 22(22):6811-6. PubMed ID: 22672801 [TBL] [Abstract][Full Text] [Related]
8. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Lamoth F; Alexander BD Antimicrob Agents Chemother; 2015 Jul; 59(7):4308-11. PubMed ID: 25896696 [TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of properties and clinical efficacy of the echinocandins. Kim R; Khachikian D; Reboli AC Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730 [TBL] [Abstract][Full Text] [Related]
10. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Wiederhold NP; Lewis RE Expert Opin Investig Drugs; 2003 Aug; 12(8):1313-33. PubMed ID: 12882619 [TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of ß-1,6-glucan inhibitors. Kitamura A Expert Opin Drug Discov; 2010 Aug; 5(8):739-49. PubMed ID: 22827797 [TBL] [Abstract][Full Text] [Related]
16. Echinocandin antifungals: review and update. Morrison VA Expert Rev Anti Infect Ther; 2006 Apr; 4(2):325-42. PubMed ID: 16597212 [TBL] [Abstract][Full Text] [Related]
17. Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. Pfaller MA; Messer SA; Rhomberg PR; Borroto-Esoda K; Castanheira M Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533234 [TBL] [Abstract][Full Text] [Related]
18. Echinocandins: the newest class of antifungals. Sucher AJ; Chahine EB; Balcer HE Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014 [TBL] [Abstract][Full Text] [Related]